• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Neuropace Inc.

    3/3/26 5:29:33 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    S-8 1 d111115ds8.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on March 3, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NeuroPace, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   22-3550230

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    455 N. Bernardo Avenue

    Mountain View, California 94043

    (650) 237-2700

    (Address of Principal Executive Offices) (Zip Code)

    NeuroPace, Inc. 2021 Equity Incentive Plan

    NeuroPace, Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    Joel Becker

    Chief Executive Officer

    NeuroPace, Inc.

    455 N. Bernardo Avenue

    Mountain View, California 94043

    (650) 237-2700

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Mark B. Weeks

    John T. McKenna

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by NeuroPace, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) an additional 1,342,990 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and (ii) an additional 335,747 shares of Common Stock to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Registrant previously registered shares of its Common Stock for issuance under the 2021 Plan and 2021 ESPP on Registration Statements on Form S-8 filed with the Commission on April 23, 2021 (File No. 333-255453), March 11, 2022 (File No. 333-263462), March 2, 2023 (File No. 333-270246), March  5, 2024 (File No. 333-277683) and March  4, 2025 (File No. 333-285548) (collectively, the “Prior Registration Statements”).

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2021 Plan and 2021 ESPP, are incorporated herein by reference and made part of this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents By Reference.

    The following documents filed by the Registrant with the Commission (File No. 001-40337) are incorporated by reference into this Registration Statement:

    (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 3, 2026; and

    (b) the description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on April 14, 2021 under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. The Registrant is not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     

              Incorporated by Reference  

    Exhibit
    Number

      

    Description

       Schedule
    Form
         File
    Number
         Exhibit      Filing Date  
      4.1    Amended and Restated Certificate of Incorporation of the Registrant.      8-K        001-40337        3.1        April 26, 2021  
      4.2    Amended and Restated Bylaws of the Registrant.      S-1/A        333-254663        3.4        April 14, 2021  
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of Cooley LLP (included in Exhibit 5.1).            
     23.2*    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.            
     24.1*    Power of Attorney (included on the signature page of this Form S-8).            
     99.1    2021 Equity Incentive Plan.      S-1/A        333-254663        10.6        April 14, 2021  
     99.2    2021 Employee Stock Purchase Plan.      S-1/A        333-254663        10.8        April 14, 2021  
    107*    Filing Fee Table.            
     
    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on this 3rd day of March 2026.

     

    NeuroPace, Inc.

    By:

     

    /s/ Joel Becker

     

    Joel Becker

     

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joel Becker and Patrick F. Williams, and each of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her in any and all capacities, to sign the Registration Statement on Form S-8 of NeuroPace, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Joel Becker

    Joel Becker

      

    Director and Chief Executive Officer

    (Principal Executive Officer)

      March 3, 2026

    /s/ Patrick F. Williams

    Patrick F. Williams

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      March 3, 2026

    /s/ Lisa Andrade

    Lisa Andrade

       Director   March 3, 2026

    /s/ Frank Fischer

    Frank Fischer

       Director   March 3, 2026

    /s/ Uri Geiger

    Uri Geiger

       Director   March 3, 2026

    /s/ Scott Huennekens

    Scott Huennekens

       Director   March 3, 2026

    /s/ Rakhi Kumar

    Rakhi Kumar

       Director   March 3, 2026

    /s/ Joseph S. Lacob

    Joseph S. Lacob

       Director   March 3, 2026

    /s/ Renee Ryan

    Renee Ryan

       Director   March 3, 2026
    Get the next $NPCE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 101,960 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    3/2/26 4:46:29 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.48% to 74,964 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    3/2/26 12:51:28 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 3,412 shares, decreasing direct ownership by 4% to 75,322 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    2/23/26 5:31:37 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

    -- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To

    3/3/26 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's in

    2/20/26 4:30:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    --Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- -- 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE)-- --IGE is expected following potential approval in the second half of 2026-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million,

    1/13/26 7:30:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on NeuroPace with a new price target

    H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

    5/28/25 9:08:28 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on NeuroPace with a new price target

    UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

    1/21/25 8:23:18 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

    3/14/24 8:11:10 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    SEC Filings

    View All

    SEC Form S-8 filed by Neuropace Inc.

    S-8 - NeuroPace Inc (0001528287) (Filer)

    3/3/26 5:29:33 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Neuropace Inc.

    10-K - NeuroPace Inc (0001528287) (Filer)

    3/3/26 4:54:02 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NeuroPace Inc (0001528287) (Filer)

    3/3/26 4:09:13 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Financials

    Live finance-specific insights

    View All

    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

    -- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To

    3/3/26 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's in

    2/20/26 4:30:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    --Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- -- 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE)-- --IGE is expected following potential approval in the second half of 2026-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million,

    1/13/26 7:30:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 6:30:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 3:36:16 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    10/3/24 4:46:48 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroPace Announces Strategic CFO Transition

    Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

    6/24/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Continues to Strengthen Management Team

    MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

    10/16/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Strengthens Management Team with Two Key Appointments

    Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

    9/4/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care